Combination therapy for early-stage liver cirrhosis from hepatitis B
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests whether combining peginterferon alfa-2b with standard antiviral drugs can help people with early-stage liver cirrhosis caused by hepatitis B. The goal is to improve liver health and slow or stop the disease from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis (scarring of the liver) caused by hepatitis B, but it is not yet advanced or causing severe symptoms.
- You are between 18 and 60 years old.
- If you are a woman who can have children, you must have a negative pregnancy test and use effective birth control during the study and for 6 months after.
- You do not have other liver diseases (such as fatty liver, alcohol-related liver damage, or autoimmune hepatitis) or a history of liver cancer.
- You have no serious health conditions affecting your heart, lungs, blood, kidneys, or mental health.
- You have not taken part in another clinical trial in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether extra treatment with peginterferon (a drug that boosts the immune system) can help lower the amount of hidden hepatitis B virus in the liver after you've already reached clinical cure. You'll have two liver biopsies to measure this, and the findings may help prevent the virus from coming back.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
This study tests a combination of two medicines for chronic hepatitis B: pegylated interferon and a nucleoside analogue. The goal is to see if this combo helps clear the hepatitis B surface antigen and improves the chance of a functional cure.
This study tests a drug called peginterferon alfa-2b for people with advanced liver cancer that cannot be removed by surgery and who also have hepatitis B. The drug aims to boost the immune system to fight the cancer and may help control the disease.
Hear when a new HBV-related Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.